Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of VV116 (Deuremidevir) in Mild to Moderate COVID-19
NCT05582629Phase 3Completed
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing VV116 with Placebo (2 arms). Primary endpoint: Time to sustained clinical recovery at 28 days. Started Oct 2022; status: completed.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05582629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582629.